Logo image of CTNM

CONTINEUM THERAPEUTICS INC-A (CTNM) Stock Fundamental Analysis

NASDAQ:CTNM - US21217B1008 - Common Stock

10.45 USD
+0.4 (+3.98%)
Last: 8/29/2025, 6:18:16 PM
10.45 USD
0 (0%)
After Hours: 8/29/2025, 6:18:16 PM
Fundamental Rating

3

Overall CTNM gets a fundamental rating of 3 out of 10. We evaluated CTNM against 193 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for CTNM as it has an excellent financial health rating, but there are worries on the profitability. CTNM has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CTNM has reported negative net income.
In the past year CTNM has reported a negative cash flow from operations.
CTNM Yearly Net Income VS EBIT VS OCF VS FCFCTNM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 0 20M -20M -40M

1.2 Ratios

Looking at the Return On Assets, with a value of -19.85%, CTNM is in the better half of the industry, outperforming 60.10% of the companies in the same industry.
With a decent Return On Equity value of -21.34%, CTNM is doing good in the industry, outperforming 66.84% of the companies in the same industry.
Industry RankSector Rank
ROA -19.85%
ROE -21.34%
ROIC N/A
ROA(3y)-16.78%
ROA(5y)N/A
ROE(3y)-21.62%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CTNM Yearly ROA, ROE, ROICCTNM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 -20 -40 -60

1.3 Margins

CTNM does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CTNM Yearly Profit, Operating, Gross MarginsCTNM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 10 20 30 40

More info and screens

8

2. Health

2.1 Basic Checks

CTNM does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CTNM has more shares outstanding
There is no outstanding debt for CTNM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CTNM Yearly Shares OutstandingCTNM Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 5M 10M 15M 20M 25M
CTNM Yearly Total Debt VS Total AssetsCTNM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

An Altman-Z score of 10.99 indicates that CTNM is not in any danger for bankruptcy at the moment.
CTNM has a better Altman-Z score (10.99) than 88.08% of its industry peers.
There is no outstanding debt for CTNM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 10.99
ROIC/WACCN/A
WACC9.94%
CTNM Yearly LT Debt VS Equity VS FCFCTNM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 50M 100M 150M

2.3 Liquidity

A Current Ratio of 20.69 indicates that CTNM has no problem at all paying its short term obligations.
With an excellent Current ratio value of 20.69, CTNM belongs to the best of the industry, outperforming 91.19% of the companies in the same industry.
CTNM has a Quick Ratio of 20.69. This indicates that CTNM is financially healthy and has no problem in meeting its short term obligations.
CTNM has a better Quick ratio (20.69) than 91.19% of its industry peers.
Industry RankSector Rank
Current Ratio 20.69
Quick Ratio 20.69
CTNM Yearly Current Assets VS Current LiabilitesCTNM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for CTNM have decreased strongly by -341.52% in the last year.
The Revenue for CTNM has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)-341.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-58.97%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, CTNM will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.04% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y48.65%
EPS Next 2Y19.9%
EPS Next 3Y14.04%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CTNM Yearly Revenue VS EstimatesCTNM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2025 10M 20M 30M 40M
CTNM Yearly EPS VS EstimatesCTNM Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CTNM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CTNM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CTNM Price Earnings VS Forward Price EarningsCTNM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CTNM Per share dataCTNM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

CTNM's earnings are expected to grow with 14.04% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.9%
EPS Next 3Y14.04%

More info and screens

0

5. Dividend

5.1 Amount

CTNM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CONTINEUM THERAPEUTICS INC-A

NASDAQ:CTNM (8/29/2025, 6:18:16 PM)

After market: 10.45 0 (0%)

10.45

+0.4 (+3.98%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-05 2025-08-05/amc
Earnings (Next)11-04 2025-11-04
Inst Owners83.52%
Inst Owner Change-7.97%
Ins Owners1.82%
Ins Owner Change0%
Market Cap293.02M
Analysts86.67
Price Target23.26 (122.58%)
Short Float %1.29%
Short Ratio1.11
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-11.96%
Min EPS beat(2)-28.28%
Max EPS beat(2)4.35%
EPS beat(4)1
Avg EPS beat(4)-172.64%
Min EPS beat(4)-656.61%
Max EPS beat(4)4.35%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.33%
PT rev (3m)-8.06%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)1.2%
EPS NY rev (3m)-6.4%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-28.58%
Revenue NY rev (3m)-14.29%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.48
P/tB 1.48
EV/EBITDA N/A
EPS(TTM)-2.2
EYN/A
EPS(NY)-2.76
Fwd EYN/A
FCF(TTM)-1.19
FCFYN/A
OCF(TTM)-1.17
OCFYN/A
SpS0
BVpS7.06
TBVpS7.06
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -19.85%
ROE -21.34%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-16.78%
ROA(5y)N/A
ROE(3y)-21.62%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 199.23%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 20.69
Quick Ratio 20.69
Altman-Z 10.99
F-Score2
WACC9.94%
ROIC/WACCN/A
Cap/Depr(3y)149.13%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-341.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-58.97%
EPS Next Y48.65%
EPS Next 2Y19.9%
EPS Next 3Y14.04%
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-416.56%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-64.43%
EBIT Next 3Y-46.64%
EBIT Next 5YN/A
FCF growth 1Y-276.18%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-269.75%
OCF growth 3YN/A
OCF growth 5YN/A